BACKGROUND: Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking. OBJECTIVE: We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy. METHODS: BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies. RESULTS: One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV1 (3.05 vs 2.91 L, P = .001), FEV1/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV1 and FEV1/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed. CONCLUSIONS: Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted.
BACKGROUND: Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking. OBJECTIVE: We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy. METHODS: BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies. RESULTS: One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV1 (3.05 vs 2.91 L, P = .001), FEV1/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV1 and FEV1/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed. CONCLUSIONS: Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted.
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: S C Lazarus; H A Boushey; J V Fahy; V M Chinchilli; R F Lemanske; C A Sorkness; M Kraft; J E Fish; S P Peters; T Craig; J M Drazen; J G Ford; E Israel; R J Martin; E A Mauger; S A Nachman; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: Richard J Martin; Stanley J Szefler; Vernon M Chinchilli; Monica Kraft; Myrna Dolovich; Homer A Boushey; Reuben M Cherniack; Timothy J Craig; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliott Israel; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Stephen P Peters; Christine A Sorkness Journal: Am J Respir Crit Care Med Date: 2002-05-15 Impact factor: 21.405
Authors: Anne E Dixon; Emmanuelle M Clerisme-Beaty; Elizabeth A Sugar; Rubin I Cohen; Jason E Lang; Ellen D Brown; Joel E Richter; Charles G Irvin; John G Mastronarde Journal: J Asthma Date: 2011-08-08 Impact factor: 2.515
Authors: Mihaela Teodorescu; Oleg Broytman; Douglas Curran-Everett; Ronald L Sorkness; Gina Crisafi; Eugene R Bleecker; Serpil Erzurum; Benjamin M Gaston; Sally E Wenzel; Nizar N Jarjour Journal: J Allergy Clin Immunol Pract Date: 2015-05-21
Authors: Ryan M Dunn; Erik Lehman; Vernon M Chinchilli; Richard J Martin; Homer A Boushey; Elliot Israel; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira L Lugogo; Stephen P Peters; Christine A Sorkness; Stanley Szefler; Michael E Wechsler Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Kelly Wong McGrath; Nikolina Icitovic; Homer A Boushey; Stephen C Lazarus; E Rand Sutherland; Vernon M Chinchilli; John V Fahy Journal: Am J Respir Crit Care Med Date: 2012-01-20 Impact factor: 21.405
Authors: Ruby Fernandez-Boyanapalli; Elena Goleva; Christena Kolakowski; Elysia Min; Brian Day; Donald Y M Leung; David W H Riches; Donna L Bratton; E Rand Sutherland Journal: J Allergy Clin Immunol Date: 2012-11-13 Impact factor: 10.793
Authors: Anikó Bohács; Eva Pállinger; Lilla Tamási; János Rigó; Zsolt Komlósi; Veronika Müller; Yang Dong; Pál Magyar; András Falus; György Losonczy Journal: Inflamm Res Date: 2010-01 Impact factor: 4.575